INARI MEDICAL, INC. Financials Inari Medical, Inc.
Equities
NARI
US45332Y1091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.03 USD | +0.10% |
|
+9.40% | -35.26% |
| 03/05 | Inari Medical Insider Sold Shares Worth $1,619,047, According to a Recent SEC Filing | MT |
| 01/05 | Inari Medical Shares Jump on Higher Q1 Revenue | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,252 | 4,582 | 3,410 | 3,739 | 2,444 | - | - |
| Enterprise Value (EV) 1 | 4,088 | 4,406 | 3,084 | 3,623 | 2,363 | 2,329 | 2,342 |
| P/E ratio | 323 x | 507 x | -116 x | -2,164 x | -46 x | 297 x | 86.5 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 30.4 x | 16.5 x | 8.89 x | 7.57 x | 4.08 x | 3.46 x | 2.96 x |
| EV / Revenue | 29.3 x | 15.9 x | 8.04 x | 7.34 x | 3.95 x | 3.3 x | 2.84 x |
| EV / EBITDA | 206 x | 288 x | -147 x | 433 x | -99.6 x | 99 x | 38.3 x |
| EV / FCF | -76.4 x | 372 x | -129 x | 116 x | -454 x | 157 x | 57.3 x |
| FCF Yield | -1.31% | 0.27% | -0.78% | 0.86% | -0.22% | 0.64% | 1.75% |
| Price to Book | 21.5 x | 19.2 x | 8.23 x | 7.93 x | 5.8 x | 5.62 x | 5.13 x |
| Nbr of stocks (in thousands) | 48,711 | 50,205 | 53,653 | 57,590 | 58,138 | - | - |
| Reference price 2 | 87.29 | 91.27 | 63.56 | 64.92 | 42.03 | 42.03 | 42.03 |
| Announcement Date | 09/03/21 | 23/02/22 | 27/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51.13 | 139.7 | 277 | 383.5 | 493.6 | 598.6 | 705.4 | 824.7 |
| EBITDA 1 | - | 19.8 | 15.3 | -20.98 | 8.364 | -23.71 | 23.51 | 61.12 |
| EBIT 1 | - | 18.42 | 10.84 | -28.1 | -2.371 | -39.62 | 4.724 | 35.28 |
| Operating Margin | - | 13.19% | 3.92% | -7.33% | -0.48% | -6.62% | 0.67% | 4.28% |
| Earnings before Tax (EBT) 1 | - | 13.79 | 10.68 | -26.18 | 4.246 | -44.05 | 7.326 | 35.52 |
| Net income 1 | - | 13.79 | 9.84 | -29.27 | -1.636 | -49.84 | 8.215 | 28.58 |
| Net margin | - | 9.87% | 3.55% | -7.63% | -0.33% | -8.33% | 1.16% | 3.47% |
| EPS 2 | -0.1400 | 0.2700 | 0.1800 | -0.5500 | -0.0300 | -0.9143 | 0.1417 | 0.4860 |
| Free Cash Flow 1 | - | -53.52 | 11.84 | -23.92 | 31.22 | -5.2 | 14.8 | 40.9 |
| FCF margin | - | -38.32% | 4.27% | -6.24% | 6.32% | -0.87% | 2.1% | 4.96% |
| FCF Conversion (EBITDA) | - | - | 77.42% | - | 373.23% | - | 62.94% | 66.92% |
| FCF Conversion (Net income) | - | - | 120.34% | - | - | - | 180.17% | 143.11% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 21/02/20 | 09/03/21 | 23/02/22 | 27/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 83.22 | 86.75 | 92.74 | 96.2 | 107.8 | 116.2 | 119 | 126.4 | 132.1 | 143.2 | 143.8 | 151.4 | 160.1 | 167.3 | 170.1 |
| EBITDA 1 | 3.444 | -1.983 | -8.095 | -8.018 | -4.001 | -2.365 | 0.63 | 4.285 | 3.131 | - | -10.41 | -5.22 | -0.4136 | 2.86 | 7.329 |
| EBIT 1 | 1.746 | -3.082 | -9.328 | -9.798 | -5.891 | -5.338 | -1.51 | 2.113 | -0.319 | -17.18 | -14.13 | -10.13 | -6.425 | -2.73 | 0.3203 |
| Operating Margin | 2.1% | -3.55% | -10.06% | -10.18% | -5.47% | -4.6% | -1.27% | 1.67% | -0.24% | -12% | -9.83% | -6.69% | -4.01% | -1.63% | 0.19% |
| Earnings before Tax (EBT) 1 | 1.681 | -3.129 | -8.935 | -9.313 | -4.808 | -1.194 | 3.024 | 5.59 | -3.176 | -16.09 | -15.04 | -9.695 | -5.123 | -2.014 | 1.384 |
| Net income 1 | 1.107 | -3.129 | -10.19 | -10.15 | -5.798 | -2.218 | 2.085 | 3.162 | -4.667 | -24.2 | -14.35 | -9.829 | -5.943 | -1.936 | 0.9287 |
| Net margin | 1.33% | -3.61% | -10.98% | -10.55% | -5.38% | -1.91% | 1.75% | 2.5% | -3.53% | -16.9% | -9.98% | -6.49% | -3.71% | -1.16% | 0.55% |
| EPS 2 | 0.0200 | -0.0600 | -0.1900 | -0.1900 | -0.1100 | -0.0400 | 0.0400 | 0.0500 | -0.0800 | -0.4200 | -0.2629 | -0.1800 | -0.1086 | -0.0280 | 0.0150 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 23/02/22 | 04/05/22 | 03/08/22 | 02/11/22 | 27/02/23 | 03/05/23 | 02/08/23 | 01/11/23 | 28/02/24 | 30/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 164 | 176 | 326 | 115 | 80.8 | 115 | 101 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -53.5 | 11.8 | -23.9 | 31.2 | -5.2 | 14.8 | 40.9 |
| ROE (net income / shareholders' equity) | - | 17.1% | 4.48% | -8.92% | 2.27% | -4.7% | 3.59% | 9.55% |
| ROA (Net income/ Total Assets) | - | - | - | - | 1.7% | - | - | - |
| Assets 1 | - | - | - | - | -96.15 | - | - | - |
| Book Value Per Share 2 | - | 4.070 | 4.750 | 7.720 | 8.190 | 7.250 | 7.480 | 8.200 |
| Cash Flow per Share 2 | - | 0.0400 | - | -0.2600 | 0.6300 | 0.7100 | -0.1000 | - |
| Capex 1 | - | 5.46 | - | 9.95 | 4.71 | 7.7 | 8.8 | 10.7 |
| Capex / Sales | - | 3.91% | - | 2.59% | 0.95% | 1.29% | 1.25% | 1.3% |
| Announcement Date | 21/02/20 | 09/03/21 | 23/02/22 | 27/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
42.03
USD
Average target price
64.4
USD
Spread / Average Target
+53.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.26% | 2.44B | |
| +73.37% | 12.39B | |
| -17.09% | 8.08B | |
| +16.88% | 7.25B | |
| +3.57% | 5.86B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.74% | 4.19B | |
| +3.09% | 2.07B | |
| +4.85% | 1.88B |
- Stock Market
- Equities
- NARI Stock
- Financials Inari Medical, Inc.
